Opdivo™ (nivolumab) – New indication
November 8, 2016 – The FDA approved Opdivo (nivolumab) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.
Download PDF
